Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder
ISRCTN ISRCTN02634417
ClinicalTrials.gov identifier
Public title Hope for chronically suicidal patient: evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder
Scientific title Evaluating the clinical and health services impact of dialectical behaviour therapy (DBT) in individuals with borderline personality disorder: a randomised controlled trial
Acronym N/A
Serial number at source MCT-58343
Study hypothesis To evaluate the clinical and cost effectiveness of dialectical behaviour therapy (DBT) for chronically suicidal patients with borderline personality disorder (BPD).
Lay summary
Ethics approval Research Ethics Board of Centre for Addiction and Mental Health, University of Toronto approved on 28th October 2002
Study design Randomised controlled trial
Countries of recruitment Canada
Disease/condition/study domain Borderline personality disorder (BPD)
Participants - inclusion criteria 1. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) criteria for BPD
2. Be between 18 - 60 years of age, either sex
3. Have had two Para-suicide episodes in the past 5 years with one occurring in the past 3 months
4. Have had OHIP insurance coverage for 1 year or more
5. Be literate in English
6. Provide informed consent to participate in study
7. Agree to be compliant with prescribed psychotropic medication(s)
Participants - exclusion criteria 1. Current active substance dependence disorder
2. Psychotic disorder, bipolar or dementia
3. Evidence of an organic brain syndrome or mental retardation
4. Chronic or serious physical health problem that may require hospitalisation with the next year
5. Medical condition that would preclude the psychiatric medication regimen
6. Currently engaged in DBT or in GPM at St Michael's Hospital
Anticipated start date 01/10/2002
Anticipated end date 30/09/2007
Status of trial Completed
Patient information material
Target number of participants 180
Interventions 1. Dialectical behaviour therapy (Linehan, 1993)
2. General Psychiatric Management based on the American Psychiatric Association (APA) practice guidelines

Trial details received: 12 Sept 2005
Primary outcome measure(s) Parasuicidal behaviour
Secondary outcome measure(s) 1. Psychiatric hospitalisation
2. Psychiatric symptoms
3. Anger
4. Treatment retention
5. Social functioning
Sources of funding Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-58343)
Trial website
Publications 2009 results in http://www.ncbi.nlm.nih.gov/pubmed/19755574
Contact name Dr  Shelley Frances  McMain
  Address Centre for Addiction and Mental Health
33 Russell St.
  City/town Toronto
  Zip/Postcode M5S 2S1
  Country Canada
  Tel +1 416 535 8501 ext. 6852
  Fax +1 416 595 6399
  Email shelley_McMain@camh.net
Sponsor The Centre for Addiction and Mental Health (Toronto) (Canada)
  Address 33 Russell Street
  City/town Toronto
  Zip/Postcode M5S 2S1
  Country Canada
  Sponsor website: http://www.camh.net/
Date applied 16/11/2005
Last edited 21/09/2009
Date ISRCTN assigned 16/11/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central